Introduction
The core binding factor (CBF) family comprises a set of heterodimeric regulatory proteins with vital roles in eukaryotic development. The CBF a-chains share a common DNA binding domain, runt, de®ned by homology with the Drosophila pair-rule gene Run (Kania et al., 1990) . In mammals, the a subunits are encoded by three distinct genes, CBFA1, CBFA2 and CBFA3 (Miyoshi et al., 1991; Ogawa et al., 1993a; Bae et al., 1993 Bae et al., , 1995 Levanon et al., 1994) . The CBFA1 and CBFA2 genes are expressed in a restricted set of tissues and cell types (Ogawa et al., 1993a; while the CBFA3 gene is more widely expressed (Levanon et al., 1994) . The ubiquitously expressed CBFB subunit, encoded by one gene in mammals, lacks intrinsic DNA binding activity but increases the anity of its a-chain partner for DNA (Ogawa et al., 1993b; Wang et al., 1993) .
Two genes from this family, CBFA2 and CBFB, are targets for chromosomal translocations associated with speci®c human leukaemias. The CBFA2 gene translocations include the t(8;21) CBFA2/ETO, associated with *15% acute myeloid leukaemia, the t(3;21) observed in some cases of chronic myeloid leukaemia and more rarely in therapy-related leukaemias and myelodysplasias (reviewed in Nucifora et al., 1995) and the t(12;21) TEL/CBFA2 translocation frequently found in both childhood and adult pre-B acute lymphocytic leukaemia (reviewed in Rubnitz et al., 1999) . The CBFB subunit is also disrupted by both inversion and gene deletion in acute myeloid leukaemia (Liu et al., 1993) . The striking feature of all these translocations is the production of novel chimeric proteins with oncogenic activity in which all or part of the CBF protein is fused to a heterologous partner.
Gene inactivation studies have shown that loss of either Cbfa2 or Cbfb is embryonic lethal with haemorrhaging in the central nervous system and failure of foetal liver haematopoiesis (Okuda et al., 1996; Wang et al., 1996a,b) . These observations are in accord with the expression of Cbfa2 in a wide range of haemopoetic cells and suggest that the ubiquitously expressed Cbfb functions as an important cofactor for Cbfa2. Cbfa1 is expressed in a much more restricted fashion and until gene inactivation demonstrated its crucial role in bone development (Komori et al., 1997; Otto et al., 1997) , expression had been described only in T-cells and in non-lymphoid cells such as 3T3 and Bualo rat liver cells (Ogawa et al., 1993a; Meyers et al., 1996) . A similar role in bone development is indicated for the human counterpart, CBFA1. The skeletal malformation syndrome cleidocranial dysplasia (CCD) has been shown to involve either deletion, insertion or missense mutations in the CBFA1 gene (Lee et al., 1997; Mundlos et al., 1997) .
Binding sites for CBF proteins have been identi®ed in the promoter and enhancers of many mammalian genes speci®cally transcribed in the T-, B-and myeloid lineages (Meyers et al., 1995a) . While CBFs can act either as activators or repressors of gene expression Tanaka et al., 1995a; Kogan et al., 1998) it has been demonstrated that their activator function requires protein cofactors that bind to adjacent sites on DNA (Zaiman et al., 1996) . Several in vitro transfection studies with CBFA2 fusion genes have indicated that these mutant proteins act by interfering with the activities of the normal gene product (Meyers et al., 1995b; Tanaka et al., 1995b ). This hypothesis is further supported by the observation that knock-in mice expressing an CBFA2/ETO fusion demonstrate the same phenotype as Cbfa2 null mice (Yergeau et al., 1997; Okuda et al., 1998) .
Evidence that Cbfa1 may also play a role in oncogenesis has come from the recent observation of frequent retroviral insertions at the til-1 locus in virusaccelerated lymphomas of CD2-myc transgenic mice. These insertions result in the transcriptional activation of a lymphoma-speci®c isoform of Cbfa1, suggesting that this CBF family member may act as a myc collaborator in lymphoma development. While the coding sequence of Cbfa1 is not interrupted by these insertions, suggesting that a full-length gene product may be responsible, the activated gene was found to encode at least ®ve isoforms, including two with a novel C-terminal domain unrelated to known Runt family proteins (Stewart et al., 1997) . In addition, the products expressed as a result of proviral insertion were distinct from previously described Cbfa1 forms by virtue of their distinct 5' exons and N-terminal coding sequence.
In order to identify which, if any, of these isoforms have intrinsic oncogenic potential we have generated transgenic mice expressing the most abundantly expressed tumour-speci®c form (designated G1 (Stewart et al., 1997) or p57 (van Wijnen et al., in preparation) with the N-terminal sequence MASNS) under the control of the human CD2 locus control region (LCR). The results presented in this report con®rm that Cbfa1 can collaborate with myc in T-cell oncogenesis and demonstrate that a normal full length Cbfa gene can act directly as an oncogene in vivo, when overexpressed.
Results
The CD2 LCR drives high level expression of Cbfa1 protein in the T-cell compartment and reveals an in vivo complex with Cbfb Expression of the major lymphoma isoform of Cbfa1 targeted to the T-cell compartment was achieved by cloning a 2.3 kb cDNA fragment encoding the Cbfa1-G1 isoform (Stewart et al., 1997) into the polylinker region of the human CD2 minigene vector VA hCD2 (Zhumabekov et al., 1995) . Following microinjection of embryos using a 13.5 kb CD2-Cbfa1-G1 restriction fragment (Figure 1a ), four lines of mice were generated which showed copy-number dependent expression of the CD2-Cbfa1-G1 transgene. Copy number ranged from one, in the lowest expressing line, to ®ve in the highest expressing line, G1-500. Analysis of a range of tissues from G1-500, showed a 3.5 kb transgene transcript present only in thymus, spleen and mesenteric lymph node (Figure 1b) , con®rming the targeting speci®city of the transgene. Western blot analysis of G1-500 thymocytes using an anti-C terminal Cbfa1 antibody (Stewart et al., 1997) showed a major protein species of 70 kDa at greatly elevated levels compared to control thymocytes (Figure 1c) .
To assess the ability of the Cbfa1 protein to form complexes with its binding partner Cbfb in vivo, Western blot analysis was performed with an antiCbfb monoclonal antibody following immunoprecipitation of complexes with the anti-C terminal Cbfa1 antibody. As shown in Figure 1c , the anti-Cbfb antibody detects speci®cally the Cbfb chain of the complex in G1-500 thymocytes and control T47i cells. A faint signal was also detected in one of the nontransgenic thymocyte controls (A2 ± 11) presumably due to the presence of slightly higher levels of endogenous Cbfa1 protein in that lysate. Western analysis performed on the whole cell lysate for each sample showed that the overall levels of b-subunit were comparable in control and transgenic thymocytes (data not shown).
CD2-Cbfa1-G1 mice show perturbation of thymocyte development, with a marked skew to the CD8 lineage
To examine the eects of Cbfa1 over-expression on Tcell phenotype, we analysed thymocytes isolated from CD2-Cbfa1-G1 mice and littermate controls by¯ow cytometry for the cell surface markers CD3, CD4 and CD8. In CD2-Cbfa1-G1 thymocytes, we observed a signi®cant shift in the subset ratio with increased CD8 single positive (SP) thymocytes relative to CD4, SP, CD4 CD8 double positive (DP) and CD4 CD8 double negative (DN) thymocytes ( Figure 2 and Table 1 ). Although CD2-Cbfa1-G1 thymocytes demonstrated an altered T-cell phenotype there was no consistent alteration in the size of preneoplastic thymi at post mortem or increase in thymocyte number. Thymocytes prepared from CD2-Cbfa1-G1 mice and littermate controls were gated on the basis of CD3 levels of cell surface expression in an attempt to identify the stage in development at which the observed skew arises ( Figure  2 ). The altered CD4:CD8 ratio in SP thymocytes was evident in CD3 neg , CD3 lo , and CD3 hi populations suggesting that thymocyte development was perturbed before the onset of selection, although these data do not rule out the possibility that selection events are also aected. CD4 and CD8 expression was assessed on blood and mesenteric lymph node cells of both CD2-Cbfa1-G1 transgenic and littermate control mice. The CD8 skew observed in CD2-Cbfa1-G1 thymocytes was not maintained in the peripheral T-cell compartment.
Thymocytes from CD2-Cbfa1-G1 mice show reduced survival in vitro and increased sensitivity to TGF-b
Thymocytes from healthy transgenic mice and littermate controls were placed in culture in vitro and their viability measured at 24 h intervals (Figure 3a) . Cultures of CD2-Cbfa1-G1 thymocytes showed a reduced survival rate compared to non-transgenic thymocytes. Although the dierence was small it was signi®cant (P50.001) at each time point showing that Cbfa1-expressing thymocytes have reduced viability in vitro. Interestingly, during the course of this experiment, one thymus was found to be neoplastic and the Cbfa1 perturbs T-cell development and synergises with myc F Vaillant et al explanted thymocytes died at a greatly accelerated rate ( Figure 3a , square symbols). This phenomenon was also observed in a number of separate experiments following explanation of Cbfa1 tumour cells suggesting that transformation further compromises survival in vitro.
Evidence has emerged recently of a relationship between CBF family members and transforming growth factor b (TGF-b) and its cognate receptors Ji et al., 1998) . We therefore investigated the eects of TGF-b on the survival of CD2-Cbfa1-G1 thymocytes in vitro. Thymocytes from CD2-Cbfa1-G1 mice and littermate controls were cultured with or without 1 ng/ml TGF-b and cell viability was measured at 24 h intervals. As can be seen from Figure 3b , CD2-Cbfa1-G1 thymocytes died more rapidly in the presence of TGF-b than untreated transgenic thymocytes. Although normal thymocytes were also sensitive to accelerated death in the presence of TGF-b, the eect of the transgene was more than simply additive and represented a signi®cant increase (P50.001) in the sensitivity of CD2-Cbfa1-G1 thymocytes to TGF-b growth inhibition in vitro.
As it has been reported that glucocorticoid treatment reduces Cbfa1 expression in primary osteoblasts we also investigated the eect of dexamethasone on CD2-Cbfa1-G1 thymocytes in vitro. The survival of healthy transgenic thymocytes and littermate controls cultured in the presence of dexamethasone (0.1 mM) is illustrated in Figure 3c . However, although both groups of thymocytes died faster in the presence of dexamethasone the kinetics of cell death were not signi®cantly aected by the presence of the transgene.
Taken together, these results show that the CD2-Cbfa1-G1 transgene reduces the viability of thymocytes in vitro, an eect which is accentuated in the presence of TGF-b. However, the eect is not due to a general sensitization of thymocytes to cell death since the transgene has no enhancing eect on dexamethasoneinduced apoptosis.
CD2-Cbfa1-G1 transgenic mice develop a low incidence of spontaneous lymphoma and display strongly synergistic tumour development in crosses with myc transgenic mice
Extensive monitoring of the CD2-Cbfa1-G1 transgenic mice revealed that 7/117 (6%) developed T-cell tumours between 107 ± 315 days of age whereas no littermate controls succumbed to neoplastic disease Figure 1 Targeting of the major lymphoma-speci®c isoform of Cbfa1 to the T-cell compartment. (a) A 2.3 kb cDNA restriction fragment coding for the Cbfa1-G1 isoform was cloned into the multiple cloning region of the CD2 minigene vector VA hCD2 to generate the CD2-Cbfa1-G1 transgene construct. X-G represent the exons encoded by the G1 isoform, start (ATG) and stop (TGA) codons within the construct are indicated. (b) Northern blot analysis of a range of tissues from a healthy CD2-Cbfa1-G1 transgenic animal. The ®lter was hybridized with a 32 P-labelled til-1E probe which detects a 3.5 kb transgene speci®c transcript. The same blot was rehybridized with a GAPDH probe to determine RNA loading. MLN; mesenteric lymph node. (c) Western analysis of thymocyte lysates from transgenic (A2-10,15,17) and non-transgenic littermate controls (A2-11,14,16). Mice were culled at 25 weeksof-age. Upper panel: anti-Cbfa1 C-terminal antibody, lower panel: anti-Cbfb antibody on complexes immunoprecipitated with antiCbfa1 antibody. T47i represents a mouse T-cell line expressing high levels of a number of til-1/Cbfa1 isoforms (Stewart et al., 1997) Cbfa1 perturbs T-cell development and synergises with myc F Vaillant et al during the same period. Necropsy revealed the extensive involvement of most, if not all, lymphoid tissues. The presentation at post mortem was frequently multicentric with gross enlargement of lymph nodes throughout the body. The spleen was invariably involved as was the thymus although the extent of thymic enlargement varied.
As we identi®ed the til-1/Cbfa1 gene as a potential myc-collaborating gene (Stewart et al., 1996 (Stewart et al., , 1997 we assessed the eect of crossing CD2-Cbfa1-G1 mice with CD2-myc transgenic animals. CD2-myc mice develop T-cell tumours, primarily involving the thymus, at an incidence of around 30% by 12 months of age depending on the genetic background (Stewart et al., 1993) . Mice harbouring both CD2-myc and CD2-Cbfa1-G1 transgenes showed a dramatically increased incidence and decreased latency with double transgenic animals developing lymphomas by 36 days on average (range 28 ± 47 days). The kinetics of tumour formation in these mice and the relevant control populations is illustrated in Figure 4a . The pathological pro®le in the Cbfa1/myc transgenic mice was indistinguishable from that seen in the CD2-Cbfa1-G1 animals and diered from that of the CD2-myc transgenics which generally show only restricted involvement of secondary lymphoid organs (Stewart et al., 1993) .
CD2-Cbfa1-G1 transgenic mice were also crossed on to CD2-mycER TM mice. These animals express a hybrid MYC protein fused to a modi®ed oestrogen receptor (Littlewood et al., 1995) which can be activated by the oestrogen agonist/antagonist 4-hydroxy tamoxifen (4-OHT) but is insensitive to the actions of oestradiol. Although MYC activity can be successfully modulated in CD2-mycER TM mice, untreated animals show a background spontaneous rate of thymic lymphoma, presumably due to basal activity of the MYCER fusion protein ( Figure 4b and Blyth et al., submitted) . A signi®cant acceleration in the rate of spontaneous tumour formation (i.e. in the absence of tamoxifen treatment) was observed when CD2-mycER TM mice were crossed with CD2-Cbfa1-G1 transgenic mice. 100% of double transgenic ospring died between 86 ± 186 days (Figure 4b ). The later onset of tumour development in this cross compared to CD2-myc is possibly due to low basal activity of the MYCER fusion protein in the absence of tamoxifen.
The dramatic increase in mortality rate in both myc transgenic models reveals a strong synergistic interaction between myc and the full length tumour-speci®c isoform of the Cbfa1 gene in T-cell lymphomagenesis.
Mechanism of synergy: Cbfa1 rescues the expression of CD2-myc in preleukaemic thymus
An enigmatic feature of CD2-myc mice is the fact that transgene expression cannot be detected in healthy Flow cytometric analysis of normal thymocytes isolated from CD2-Cbfa1-G1 mice and littermate controls (8 ± 30 weeks-of-age). Thymocytes were analysed as described in Figure 2 and the average+s.d. for each cell type gated on the whole population ( Figure 2 ; ®rst column) is presented
Figure 2 CD2-Cbfa1-G1 thymocytes show a marked skew towards CD8 SP cells. Flow cytometry analysis of CD4 and CD8 surface expression of thymocytes from littermate control (top row) and CD2-Cbfa1-G1 (bottom row) mice (28 weeks-of-age). Thymocytes were labelled with QR anti-CD3, PE anti-CD4, and FITC anti-CD8 prior to analysis. Each column represents the CD4CD8 pro®le gated on a speci®c CD3 population as indicated. A representative set of data (one control and one CD2-Cbfa1-G1 transgenic mouse) is shown mice, but is readily observed in lymphoma cells and in thymuses of young mice with histologically detectable neoplastic cells (Stewart et al., 1993) . While other explanations could not be excluded, we considered that the most likely explanation is that developmental activation of the CD2-myc transgene is negatively selected in normal mice unless rescued by a collaborating gene mutation. This interpretation was further supported by the profound synergy between CD2-myc and the p53 null genotype (Blyth et al., 1995) . We therefore examined the eect of the Cbfa1 transgene on preleukaemic expression of CD2-myc. As can be seen in Figure 5 , thymic RNA from 10 day-old mice carrying both transgenes showed high level expression of CD2-myc, while, as before, littermates carrying CD2-myc alone showed undetectable expression unless neoplastic outgrowth was present. Analysis of T-cell receptor b-chain rearrangements of these 10-day thymuses showed that signi®cant clonal expansion
had not yet occurred and that CD2-myc expression re¯ects a preleukaemic state. Figure 3 Reduced viability of cultured CD2-Cbfa1-G1 thymocytes. Viability of thymocytes from CD2-Cbfa1-G1 transgenic mice (inverted triangle) or littermate controls (circle) were assayed following explantation. Thymocytes from transgenic and control mice (13 weeks-of-age) were cultured and cell viability estimated daily. Cells from individual animals were cultured in triplicate and each experiment based on three transgenic and three control mice. The experiment was repeated three times and representative curves from one of these experiments is shown. (a) Cells cultured in growth medium alone. One explanted thymus was found to be neoplastic and thymocytes displayed very rapid death (square; see text). (b) Cells cultured in the absence (emtpy symbols) or in the presence (®lled symbols) of 1 ng/ml TGF-b. (c) Cells cultured in the absence (empty symbols) or in the presence (®lled symbols) of 0.1 mM dexamethasone Cbfa1 perturbs T-cell development and synergises with myc F Vaillant et al
The possibility that Cbfa1 aects CD2-regulated transgenes at the transcriptional level was considered but could not be con®rmed. Although CD2-Cbfa1-G1 synergises eciently with CD2-mycER TM , the latter transgene was found to be expressed as similar levels in tumours regardless of their Cbfa1 status. Also, the endogenous CD2 gene appeared to be unaected by the Cbfa1 transgene as measured by¯ow cytometry as CD2 + cell numbers and¯uorescence intensity were indistinguishable despite the profound eects on CD8 (data not shown).
Expression of Cbfa1 aects the tumour cell phenotype
Phenotypic analysis was carried out on cells prepared from CD2-Cbfa1-G1, Cbfa1/myc and Cbfa1/mycER TM tumours to determine the lineage and origin of the lymphomas. All lymphomas stained positively for CD3, CD4 and CD8 but negative for CD45 indicating their T-cell lineage (data not shown). The majority of CD2-Cbfa1-G1 spontaneous tumours analysed (7/8) presented as a clonal population of CD4/CD8 DP and CD8 SP cells (Figure 6a ). Thymocytes from CD2-myc tumours generally present as a CD4/CD8 DP ( Figure  6b ), or as a CD8 SP population . As seen in Figure 6d , thymocytes from CD2-mycER TM tumours comprise a CD4/CD8 DP population with a tendency towards CD4 SP (Blyth et al., submitted) . Signi®cantly, tumours arising in Cbfa1/myc and Cbfa1/ mycER TM double transgenic mice presented with an altered phenotype. In both double transgenic mice the tumour population was CD4/CD8 DP but with a very marked trend towards CD8 SP (Figure 6c ,e). This phenotype is reminiscent of the skew observed in healthy CD2-Cbfa1-G1 thymocytes (see Figure 2) . In animals which presented with multicentric lymphoma, analysis of cells from enlarged mesenteric lymph nodes showed a similar pattern of a clonal CD4/CD8 DP/ CD8 SP population. Therefore, the expression of a Cbfa1 transgene in CD2-myc transgenic mice results in the generation of a markedly dierent tumour phenotype than is normally associated with CD2-myc induced T-cell lymphomas. Figure 6 Analysis of CD4 and CD8 surface expression of neoplastic thymocytes from (a) CD2-Cbfa1-G1, (b) CD2-myc, (c) Cbfa1/ myc, (d) CD2-mycER TM and (e) Cbfa1/mycER TM mice. The data from one representative tumour for each of the above groups of mice is shown. Cells were labelled with QR anti-CD3, PE anti-CD4, and FITC anti-CD8 except in (a) where cells were labelled with PE anti-CD2, QR anti-CD4, and FITC anti-CD8 Figure 5 Cbfa1 rescues expression of the CD2-myc transgene in Cbfa1/myc preleukaemic mice. Nothern blot analysis of 10-day old thymuses of CD2-myc (lanes 1, 2, 3, 4, 6) and Cbfa1/myc (lanes 5, 7, 8, 9) transgenic mice. Filters were hybridized with the til-1E probe, stripped and rehybridized with a human c-myc exon 1 probe. RNA loading was con®rmed by stripping and rehybridization with GAPDH. EL4; mouse lymphoma T-cell line, T27i; mouse T-cell line expressing high levels of a number of til-1/Cbfa1 isoforms (Stewart et al., 1997) In vitro apoptosis induced by a regulatable myc transgene is not blocked by Cbfa1
Despite the transformed status of spontaneous CD2-mycER TM lymphomas, we have found that these generally retain sensitivity to MYC-induced death on modulation by 4-OHT treatment. This phenomenon can be observed in both primary explanted tumour cells (Figure 7a , ER150 ± 112) and in established cell lines (Figure 7e ) and is speci®c for CD2-mycER TM as survival is not aected by 4-OHT in lymphoma cells lacking the transgene. These data indicate that the To investigate possible modulation of MYC-induced death by Cbfa1, cell viability analysis was carried out in primary lymphocytes and cell lines derived from CD2-Cbfa1-G1/CD2-mycER TM tumours. Primary cells prepared from neoplastic thymuses of Cbfa1/mycER TM double transgenic mice showed signi®cantly increased cell death following tamoxifen treatment indicating that MYC-induced apoptosis was not abrogated by Cbfa1 (Figure 7a ). This pattern was also observed in Cbfa1/mycER TM derived cell lines (Figure 7b ± d) . These results show that, at least in vitro, co-expression of Cbfa1 does not override MYC-induced apoptosis.
Discussion
This study has shown that over-expression of a single isoform of Cbfa1 (G1/p57) in the T-cell compartment is sucient to predispose mice to lymphoma development. Our previous studies identi®ed the Cbfa1 gene as a frequent target for transcriptional activation by Moloney murine leukaemia virus in lymphomas of CD2-myc mice and showed that the over-expressed gene encodes multiple isoforms, the most abundant of which is G1 (Stewart et al., 1996 (Stewart et al., , 1997 . Moreover, we have found that over-expression of Cbfa1 in the thymus perturbs T-cell development, causing a pronounced skew towards CD8SP thymocytes. The Cbfa1 transgene is also strongly synergistic with myc transgenes in the induction of T-cell neoplasia and this oncogene combination induces the rapid development of tumours with a characteristic CD8SP phenotype, similar to that seen in the preneoplastic thymus of Cbfa1 transgenic mice. Finally, investigation of the mechanism of synergy between myc and Cbfa1 indicates that the latter does not act by a dominant block of MYC-induced apoptosis.
Previous observations on the involvement of CBFachain genes in cancer have been con®ned to CBFA2. This gene is a frequent target for chromosomal translocation in human myeloid and pre-B leukaemias where it is fused to one of a variety of heterologous partners (t(8;21) CBFA2/ETO; t(12;21) TEL/CBFA2; t(3;21) AML1/EVI1). In vitro studies of CBF target gene regulation have suggested that the CBFA2 fusion proteins act as dominant negative inhibitors of their normal counterparts (Meyers et al., 1995b; Tanaka et al., 1995b) and this interpretation is consistent with the eects of knocking in a CBFA2-ETO transgene which confers a phenotype similar to that induced by homozygous inactivation of the gene, with complete failure of haemopoietic development rather than neoplastic disease (Yergeau et al., 1997; Okuda et al., 1998) . In fact, the neoplastic eects of CBFA2 have not yet been successfully reproduced in transgenic mice. It is therefore interesting to compare our ®ndings, in which the over-expression of a full-length Cbfa gene induces lymphoma.
The isoform that we have expressed in CD2-Cbfa1-G1 mice diers subtly from the form expressed in normal T-cells at its N-terminus, where the ®rst ®ve amino acids are replaced by a 19 amino acid domain derived from an alternative upstream exon which is normally expressed only in bone-forming cells Stewart et al., 1997) . It is therefore conceivable that this product acts to antagonize the function of its T-cell-speci®c counterpart, or the two other Cbfa genes (Cbfa2, Cbfa3) which are coexpressed in the T-cell lineage (Levanon et al., 1994; Satake et al., 1995) . Antagonism could operate by competition of the over-expressed gene product for the common heterodimeric partner Cbfb, for CBF binding sites on DNA, or for other CBF-interacting proteins.
Our ®nding that full-length Cbfa1 forms complexes with Cbfb in vivo is in apparent con¯ict with previous studies which indicated that inhibitory sequences must be deleted from the full-length protein for it to interact with Cbfb Thirunavukkarasu et al., 1998) . However, as these conclusions were based on in vitro interaction of recombinant proteins (Thirunavukkarasu et al., 1998) or transfection of 3T3 ®broblasts , it is possible that essential binding cofactors were absent or limiting in each case. In support of this interpretation, it has recently been shown that interaction of Cbfa2 (AML1/PEBPB) with Ets1 causes mutual activation of their DNA binding potential by inactivation of inhibitory domains in each protein (Kim et al., 1999) . Further examination of the location and composition of Cbfa1-containing complexes in lymphoma cells may help to resolve this question.
Although we observed a skew in T-cell phenotype in the thymus of Cbfa1 transgenic mice, previous studies of Cbfa1 de®cient mice revealed no obvious disturbance in T-cell development (Komori et al., 1997; Otto et al., 1997; M Owen, personal communication) . These studies suggested that Cbfa1 is not essential in T-cells, although a redundant function could not be excluded as Cbfa2 and Cbfa3 are also expressed in this lineage (Levanon et al., 1994; Satake et al., 1995) . As reported here, we ®nd that the bias to CD8 in Cbfa1 transgenic mice aects thymocytes regardless of their CD3 expression status, arguing that this skew arises before repertoire selection has occurred. The eects of the transgene present an intriguing parallel to those of exogenous TGF-b on immature T-cells which induces CD8 expression without aecting cell proliferation or survival (Letterio et al., 1998) . Our recent analyses of cell cycle distribution indicate that in vivo cell survival and proliferation are unaected in tumour-free Cbfa1 transgenic mice (K Blyth, unpublished data). As TGFb receptor I expression is positively regulated by Cbfa1 in osteoblasts , it is tempting to consider that the CD8 skew in Cbfa1 transgenic mice is due to increased sensitivity to exogenous TGF-b. In accord with this possibility, we have shown here that primary thymocytes from Cbfa1 transgenic mice display increased sensitivity to TGF-b growth inhibition in vitro. As TGF-b growth inhibition operates via down-regulation of c-myc transcription (reviewed in Alexandrow et al., 1997), these observations also suggested a mechanism for the cooperation of the ectopically expressed CD2-myc transgene with Cbfa1.
How does Cbfa1 promote lymphoma development and synergise so strongly with Myc? It is clear that its role diers from other Myc-collaborators such as Bcl-2 and p53. Unlike Bcl-2, the Cbfa1 transgene does not Cbfa1 perturbs T-cell development and synergises with myc F Vaillant et al prevent tamoxifen-induced apoptotis in mycER TM expressing tumour cells in vitro. Also, unlike p53 null tumours, Cbfa1 lymphomas are not readily established in vitro. However, a possible clue to its role is provided by the observation that CD2-myc transgene expression is rescued in the preleukaemic thymus of mice carrying both genes. We have previously noted that healthy CD2-myc mice have no detectable expression of the transgene, even in thymus, and we hypothesized that the non-expressing phenotype is due to early death of expressing cells in thymic development (Stewart et al., 1993) . Our results here show that mice carrying both the CD2-Cbfa1-G1 and CD2-myc transgenes have abundant CD2-myc expression in thymus prior to the emergence of clonal malignancy. The explanation we favour is that Cbfa1 over-expression allows survival of the myc-expressing cells in vivo. The alternative possibility that synergy between Cbfa1 and CD2-myc is due to transcriptional regulation of the CD2-myc transgene seems less likely as the Cbfa1 transgene also cooperates strongly with the CD2-mycER TM transgene which is constitutively expressed in T-cells (Blyth et al., submitted) with no evident transcriptional modulation by Cbfa1.
Future work will be aimed at understanding the transcriptional programmes altered by ectopic Cbfa1 expression and the downstream eectors of its oncogenic properties.
Materials and methods

Generation of transgenic mice
CD2-Cbfa1-G1 transgenic mice were generated from C57B1/ 66CBA/Ca F2 fertilized eggs microinjected with a 13.5 kb CD2-Cbfa1-G1 restriction fragment (Figure 1 ). CD2-mycER TM mice were generated following a similar protocol using a 14 kb CD2-mycER TM restriction fragment coding for the human c-myc cDNA fused to a mutated murine estrogen receptor (Littlewood et al., 1995) which can be regulated by tamoxifen treatment in vivo (Blyth et al., submitted) . Animals heterozygous for both the CD2-Cbfa1-G1 and CD2-myc transgenes (Stewart et al., 1993) and CD2-Cbfa1-G1 and CD2-mycER TM were subsequently bred to achieve Cbfa1/myc and Cbfa1/mycER TM double transgenic mice. Genotypes of mice were identi®ed by Southern blot hybridization analysis on DNA extracted after tail biopsy.
DNA hybridization analysis
High molecular weight genomic DNA from mouse tissues was prepared using the Nucleon II kit (Scotlab). DNA digestion with restriction enzymes was carried out according to manufacturers instructions, fragments separated on 0.8% agarose gels and transferred to Hybond N membrane (Amersham Pharmacia Biotech Ltd.) in 206SSC. Filters were hybridized in 66SSC at 658C overnight, washed at high stringency (3620 min, 0.16SSC, 0.5% SDS, 608C) and exposed to X-ray ®lm.
RNA extraction and blot hybridization
Total cellular RNA was prepared from mouse tissues and cell lines using RNAzolB (Biogenesis, Bournemouth, UK). 20 mg samples were separated by electrophoresis on 1% agarose gels containing 2.2 M formaldehyde, transferred to Hybond N membrane in 106SSC and hybridized overnight at 428C in 50% formamide. Filters were washed at high stringency as described for DNA blots.
Probes
Probes were radiolabelled by random priming using a-32 PdCTP (3000 Ci/mmole, Amersham Pharmacia Biotech Ltd.) to speci®c activities 45610 8 c.p.m./mg. Transgene sequences were detected as follows: CD2-Cbfa1-G1: 800 bp til-1E PCR fragment (Stewart et al., 1997) , CD2-myc and CD2-mycER TM ; human c-myc exon 3 restriction fragment (Stewart et al., 1993) . Expression of the transgene sequences was detected as follows: CD2-Cbfa1-G1; til-1E fragment, and CD2-myc; human c-myc exon 1 PCR fragment (Stewart et al., 1993) . To assess RNA loading GAPDH, glyceraldehyde 3-phosphate. Rearrangement of T-cell receptor b-chain genes was determined by hybridization with a 1.2 kb EcoRI fragment of clone 86T5 (Hedrick et al., 1984) .
Western blot analysis
Cells were lysed in 100 ml RIPA buer (150 mM NaCl, 50 mM Tris (pH 8.0), 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) in the presence of protease inhibitors for 1 h at 48C. Following centrifugation, the supernatant was mixed with an equal volume of loading buer. 2.5 to 5610 4 cells were separated by electrophoresis on a 8% SDS-polyacrylamide gel and transferred onto Immobilon-P membrane (Millipore). Following blocking (5% milk powder in PBS containing 1% BSA and 0.1% Tween-20) for a minimum of 1 h at room temperature, the membrane was incubated at 48C overnight with anti-C terminal Cbfa1 antibody (1 : 1000 dilution) (Stewart et al., 1997) . Following three washes (0.05% Tween-20 in PBS), the secondary antibody (peroxidase conjugated anti-rabbit antibody; 1 : 1000 dilution) was applied for 1 h at room temperature. ECL detection was carried out following the manufacturer's instructions (Amersham Pharmacia Biotech Ltd.). For the detection of the Cbfb chain, cells were lysed in SDS-free RIPA buer for 1 h at 48C prior to centrifugation. The supernatant was incubated in the presence of Cbfa1 antibody (1 : 40 dilution) and 4 ml protein G Plus-agarose beads (Calbiochem) at 48C overnight on a tube rotator. The beads were washed four times in 200 ml SDS-free RIPA buer, centrifuged and resuspended in 20 ml loading buer. Immunoprecipitated proteins were separated on a 15% SDS-polyacrylamide gel and a mouse monoclonal anti-human Cbfb antibody (generous gift from N Speck) was applied to the membrane overnight. Cbfb was detected by ECL after incubation with an anti-mouse peroxidaseconjugated secondary antibody (Sigma).
Flow cytometry analysis of isolated thymocytes
Tumour/thymus tissue was disaggregated in RPMI (LifeTechnologies) containing 10% FCS, 2 mM glutamate, 50 mM b-mercaptoethanol and penicillin/streptomycin, using scalpel blades. Viable cells were isolated on a Ficoll-Paque (Amersham Pharmacia Biotech Ltd.) density gradient at 3000 r.p.m. for 10 min and washed in cold phosphatebuered saline (PBS) containing 0.1% BSA and 0.01% sodium azide. 1 ± 2.5610 6 cells were directly labelled for 30 min at 48C using a combination of rat monoclonal antibodies: Quantum Red (QR) conjugated anti-CD3 (Sigma), PE conjugated anti-CD4 (Serotec), FITC conjugated anti-CD8 (Serotec), PE conjugated anti-CD2 (Serotec) and QR conjugated anti-CD4 (Sigma). Cells were washed four times in cold PBS/BSA/sodium azide, resuspended in 200 ± 400 ml PBS/BSA/sodium azide and analysed on a Coulter Epics Elite¯ow cytometer.
Thymocyte survival in vitro
Thymocytes were prepared as described above. Cells were cultured in complete RPMI medium (RPMI-1640 plus 10% FCS containing 2 mM glutamate, 50 mM b-mercaptoethanol and penicillin/streptomycin) at 1 ± 2610 6 cells per ml in 24-Cbfa1 perturbs T-cell development and synergises with myc F Vaillant et al well plates. Viable cell numbers were determined daily by trypan blue exclusion using 0.4% trypan blue solution (Sigma). All cultures were performed in triplicate or quadruplicate. 4-hydroxytamoxifen (Sigma), prepared in ethanol, was added to CD2-mycER TM cells at a ®nal concentration of 250 nM. Equivalent volumes of ethanol were added to control samples. TGF-b (Boehringer Mannheim) was added to a ®nal concentration of 1 ng/ml. Dexamethasone (Sigma) was used at 0.1 mM. Statistical analysis was carried out using the Students t-test.
